BIODESIX, INC. Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
BIODESIX, INC. (BDSX) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $329.70 million as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2025-03-03
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $329.70M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $310.40M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $299.90M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $267.10M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration |
|---|---|
| 2024-12-31 | $329.70M 10-K · filed 2025-03-03 |
| 2023-12-31 | $310.40M 10-K · filed 2024-03-01 |
| 2022-12-31 | $299.90M 10-K · filed 2023-03-06 |
| 2021-12-31 | $267.10M 10-K · filed 2022-03-14 |
| 2020-12-31 | $233.60M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |